Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2456326 | 0.81 | TSHR (0.31) | MAPT | |
| SCHEMBL2245503 | 0.76 | — | — | |
| SCHEMBL5640318 | 0.74 | — | — | |
| SCHEMBL5644679 | 0.74 | — | — | |
| SCHEMBL6138233 | 0.70 | — | — | |
| SCHEMBL7623161 | 0.70 | — | — | |
| SCHEMBL1049806 | 0.64 | — | — | |
| SCHEMBL7638199 | 0.62 | — | — | |
| SCHEMBL1049678 | 0.60 | — | — | |
| SCHEMBL9320067 | 0.60 | BRD4 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-06-22 | — | — | US | claimed |
| EP-4143191-A2 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | iOmx Therapeutics AG (DE) | 2023-03-08 | — | — | EP | claimed |
| WO-2021219731-A2 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-11-04 | — | — | WO | claimed |
| CN-111393359-A | Pyridine salt-containing N- (cinnamoyl) -N' - (substituted) propyl hydrazide compound and preparation method and application thereof | 贵州大学 | 2020-07-10 | — | — | CN | claimed |
| EP-2920189-B1 | PROCESS FOR MAKING NOVEL CHIRAL PHOSPHORUS LIGANDS | BOEHRINGER INGELHEIM INT (DE) | 2017-08-02 | — | — | EP | claimed |
| EP-2920189-A1 | PROCESS FOR MAKING NOVEL CHIRAL PHOSPHORUS LIGANDS | Boehringer Ingelheim International GmbH (DE) | 2015-09-23 | — | — | EP | claimed |
| US-8816112-B2 | Process for making novel chiral phosphorus ligands | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-26 | — | — | US | claimed |
| WO-2014078491-A1 | PROCESS FOR MAKING NOVEL CHIRAL PHOSPHORUS LIGANDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-22 | — | — | WO | claimed |
| US-20140135506-A1 | PROCESS FOR MAKING NOVEL CHIRAL PHOSPHORUS LIGANDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-15 | — | — | US | claimed |
| CN-1112118-A | Epi-epibatidine derivatives | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1995-11-22 | — | — | CN | claimed |
| EP-0657455-A1 | Epi-epibatidine derivatives, a process and intermediates for preparing them and epi-epibatidine and medicaments containing the epi-epibatidine derivatives and/or epi-epibatidine and the use of them | EGIS GYOGYSZERGYAR (HU) | 1995-06-14 | — | — | EP | claimed |
| EP-3318555-B1 | BIFUNCTIONAL CHELATING AGENTS | BWXT MEDICAL LTD (CA) | 2023-08-16 | — | — | EP | disclosed |
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-06-22 | — | — | US | disclosed |
| EP-4143191-A2 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | iOmx Therapeutics AG (DE) | 2023-03-08 | — | — | EP | disclosed |
| WO-2021219731-A2 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-11-04 | — | — | WO | disclosed |
| CN-1112118-A | Epi-epibatidine derivatives | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1995-11-22 | — | — | CN | disclosed |
| EP-0657455-A1 | Epi-epibatidine derivatives, a process and intermediates for preparing them and epi-epibatidine and medicaments containing the epi-epibatidine derivatives and/or epi-epibatidine and the use of them | EGIS GYOGYSZERGYAR (HU) | 1995-06-14 | — | — | EP | disclosed |
| EP-0072013-B1 | PYRROLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | MERCK & CO. INC. (US) | 1986-04-16 | — | — | EP | disclosed |
| US-4434175-A | 5-AROYL-PYRROLE ALKANOIC ACIDS | MERCK & CO., INC. (US) | 1984-02-28 | — | — | US | disclosed |
| EP-0072013-A1 | Pyrrole compounds as anti-inflammatory and analgesic agents | MERCK & CO. INC. (US) | 1983-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135506-A1 | PROCESS FOR MAKING NOVEL CHIRAL PHOSPHORUS LIGANDS | PHOSPHO1, INPP5B, PLCG2 | CYP3A4 2608/4885MAPT 4123/4885 |
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | MITF, PRKDC, PRKACA | CYP3A4 4220/4885MAPT 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.